On September 12, a press conference was held at the press center of the Interfax News Agency in Ekaterinburg, dedicated to the epidemiological situation, as well as new research on the treatment of acute respiratory viral infections in children in the Sverdlovsk Region. At the moment, multicenter, randomized, double-blind, comparative, placebo-controlled clinical trials of the efficacy and safety of Triazavirin in 12-17 year old children with ARVI diagnosis have been completed.
From September 5 to 8, 2022, the IX (XXVIII) National Diabetes Congress with international participation Diabetes Mellitus and Obesity – the Non-Infectious Interdisciplinary Pandemics of the 21st Century was held in Moscow, organized by the Russian Association of Endocrinologists and the Federal State Budgetary Institution National Medical Research Center for Endocrinology of the Ministry of Health of Russia. Among the leading domestic and foreign companies producing medicines, the Medsintez Plant presented its main products at the booth – preparations of genetically engineered and analogue human insulin Rosinsulin.
The issue of replacing imported goods with their domestic counterparts is particularly acute for Russia today: the large-scale sanctions imposed against the Russian Federation recently have gone “live”. At the same time, there are enterprises in the Urals that have been working for a long time under the import substitution program and, perhaps, have prepared better than others for the events that have come: about one of these productions — in the “Federalpress” material.
The ban on the import of medicines and raw materials for their production into Russia by foreign companies is becoming an incentive for the rapid development of domestic pharmaceuticals. The pharmaceutical company Medsintez is a leading plant in the Urals for the production of medicines. Its representatives declare: “It is a high-tech production which is able to provide the Russian market with almost any import-substituting drugs, which is facilitated by a strong scientifi c base of the enterprise and its powerful equipment.” Indeed, the quality of the company’s products has been marked with the highest awards, and the production itself is a guarantor of drug safety in Russia. We learned about the history of the Medsintez innovative plant, its capabilities, its own development of raw materials, expansion of the product line, international cooperation, as well as the development and import substitution in the field of pharmaceuticals at the enterprise.
On June 3, 2022, Vyacheslav Yakovlevich Tyumentsev, Head of the Novouralsk Urban District, visited the production facilities of the Medsintez Plant and discussed plans for future cooperation with the management of the enterprise aimed at developing and improving the social life of the town. During the visit, Vyacheslav Yakovlevich noted the high-tech production of vital medicines of the plant, its capacity, high potential for expanding and creating new import-substituting medicines, components necessary for the country's pharmaceutical industry under the sanctions policy of Western countries. The head of the NUD expressed gratitude on behalf of the Administration for the confidence in the drug safety of the district and the country as a whole.
Этот сайт использует файлы cookie для хранения данных. Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами. Вы можете отказаться от использования cookies, выбрав соответствующие настройки в браузере.
